Advertisement

Hardened Reverse Micelles as Drug Delivery Systems

  • P. Speiser
Chapter
Part of the Forschung Soziologie book series

Abstract

Micelles and microemulsions are elegant systems for drug delivery through solubilization of lipophilic drugs and transdermal or parenteral application of drugs. The disadvantage of such systems is mainly the lack of shelf stability and poor resistance to heat which is necessary for antimicrobial treatment. The main reason for this instability is the loose and mobile liquid nature of the micelle membrane and consequently the high degree of molecular motions, and the varying permeability for drug molecules with changing temperatures. One way to eliminate this instability could be to harden the micelle itself or its membrane, so as to get a vesicle with a solid amorphous wall.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Fikentschen, H. Gerrens and H. Schuller, Angew. Chem. 72: 856 (1960).CrossRefGoogle Scholar
  2. 2.
    H.R. Allcock, Angew. Chem. 89: 153 (1977).CrossRefGoogle Scholar
  3. 3.
    T.M.S. Chang, Science 146: 524 (1964).CrossRefGoogle Scholar
  4. 3a.
    T.M.S. Chang, Canad. J. Physiol. Pharmacol. 44: 115 (1966).CrossRefGoogle Scholar
  5. 3b.
    T.M.S. Chang, Canad. J. Physiol. Pharmacol. 47: 1043 (1969).CrossRefGoogle Scholar
  6. 4.
    G. Birrenbach and P. Speiser, J. Pharm. Sci. 65 1763 (1976).CrossRefGoogle Scholar
  7. 5.
    A.E. Alexander and P. Johnson, Colloid Science, Vol. II, Clarendon Press Oxford, p. 686 (1949).Google Scholar
  8. 6.
    P. Speiser, Progr. Colloid Polymer Sci. 59: 48 (1976).CrossRefGoogle Scholar
  9. 6a.
    P. Speiser and G. Birrenbach, U.S. Patent 4 021 364 (1977).Google Scholar
  10. 7.
    J.T. Dingle, P.J. Jacques and I.H. Shaw, Lysosomes in Appl. Biology and Therapeutics 6, North Holland Publ. Comp., chapter 23, page 653 (1979).Google Scholar
  11. 8.
    P. Couvreur, P. Tulkens, M. Roland, A. Trouet and P. Speiser, FEBS Lett. 84: 323 (1977).CrossRefGoogle Scholar
  12. 9.
    H. Kopf, Thesis ETH-Zürich (1975).Google Scholar
  13. 9a.
    H. Kopf, R.K. Joshi, M. Soliva and P. Speiser, Pharm. Ind. 38: 281 (1976).Google Scholar
  14. 9b.
    H. Kopf, R.K. Joshi, M. Soliva and P. Speiser, Pharm. Ind. 39: 993 (1977).Google Scholar
  15. 10.
    G. Birrenbach, Thesis ETH-Zürich (1973).Google Scholar
  16. 11.
    J. Kreuter, R. Mauler, H. Gruschkau and P. Speiser, Exp. Cell. Biol. 44: 12 (1976).Google Scholar
  17. 11a.
    J. Kreuter and P. Speiser, Infect. Immun. 13: 204 (1976).Google Scholar
  18. 11b.
    J. Kreuter and P. Speiser, J. Pharm. Sci. 65: 1624 (1976).CrossRefGoogle Scholar
  19. 12.
    P. Couvreur et al. in press (1982).Google Scholar
  20. 13.
    W.W. Nowinsky, Fundamental Aspects of Normal and Malignant Growth, Elsevier, Amsterdam (1958).Google Scholar
  21. 14.
    D.E. Nicholson, Metabolic Pathways, Koch-Light Lab. Colnbrook, Bucks, England (1968).Google Scholar
  22. 15.
    M. Pantůčtek, Talanta 14: 643 (1967).CrossRefGoogle Scholar
  23. 16.
    Proceedings of the Meran Symposium 1982, Schriftenreihe Bundesapothekerkammer, Gelbe Reihe, Band X (1982).Google Scholar
  24. 17.
    D.W. Lübbers, N. Opitz, P. Speiser and H. Bisson, Z. Naturforsch. 32c: 133 (1977).Google Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • P. Speiser
    • 1
  1. 1.School of Pharmacy ETHZürichSwitzerland

Personalised recommendations